2026 ICD-10-CM Diagnosis Code C61Malignant neoplasm of prostate

ICD-10-CM CodesC00–D49C60-C63C61

ICD-10-CM C61
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C61 is a billable ICD-10-CM diagnosis code for malignant neoplasm of prostate. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 715 through 716, 722 through 724. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Male reproductive system cancers - prostate.

Code Identity

ICD-10-CM Code
C61
Billable Status
Yes — Valid for Submission
Code Describes
Malignant neoplasm of prostate
Chapter
C60-C63
Malignant neoplasms of male genital organs

Code Classification

ChapterC00–D49Neoplasms
SectionC60-C63Malignant neoplasms of male genital organs
CategoryC61Malignant neoplasm of prostate
This CodeC61Malignant neoplasm of prostate

Quality Payment Program MeasuresBilling

Medicare quality measures that can apply when C61 is part of the patient record.

Radical Prostatectomy Pathology Reporting

High Priority: NO

Measure Type: Process

Submission Methods: Claims, Registry

Description: Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Acinar cell cystadenocarcinoma of prostate
  • Adenocarcinoma of prostate
  • Carcinoma of prostate
  • Endometrioid carcinoma of prostate
  • Extraprostatic extension of tumor present
  • Extraprostatic extension of tumor present, focal
  • Extraprostatic extension of tumor present, multifocal
  • Extraprostatic extension of tumor present, non-focal
  • Extraprostatic extension of tumor present, unifocal
  • Familial prostate cancer
  • Hormone refractory prostate cancer
  • Hormone sensitive prostate cancer
  • Infiltrating duct carcinoma of prostate
  • Local recurrence of malignant neoplasm of prostate
  • Malignant neoplasm involving urinary bladder by direct extension from prostate
  • Malignant neoplasm of prostate
  • Malignant neoplasm of seminal vesicle
  • Malignant tumor involving an organ by direct extension from prostate
  • Malignant tumor involving rectum by direct extension from prostate
  • Malignant tumor involving seminal vesicle by direct extension from prostate
  • Malignant tumor involving urethra by direct extension from prostate
  • Malignant tumor involving vasa deferentia by direct extension from prostate
  • Metastatic castration-resistant prostate cancer
  • Neoplasm of seminal vesicle
  • Non-metastatic prostate cancer
  • Obstructive nephropathy due to malignancy
  • Obstructive nephropathy due to prostate cancer
  • Primary acinar cell cystadenocarcinoma of prostate
  • Primary adenocarcinoma of prostate
  • Primary carcinoma of prostate
  • Primary endometrioid carcinoma of prostate
  • Primary infiltrating duct carcinoma of prostate
  • Primary malignant hormone-refractory neoplasm of prostate
  • Primary malignant neoplasm of prostate
  • Prostate cancer metastatic to eye
  • Recurrent malignant neoplasm of prostate
  • Squamous cell carcinoma of male genital
  • Squamous cell carcinoma of prostate
  • Tumor invasion of perineural tissue absent
  • Tumor invasion of perineural tissue present
  • Tumor invasion of periprostatic fat absent

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Use Additional Code

  • code, if applicable, to identify:
  • hormone sensitivity status Z19.1 Z19.2
  • rising PSA following treatment for malignant neoplasm of prostate R97.21

Type 1 Excludes

  • malignant neoplasm of seminal vesicle C63.7

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Adenocarcinoma
      • duct
        • unspecified site
          • male
    • Carcinoma(malignant)
      • endometrioid
        • unspecified site
          • male
    • Cystadenocarcinoma
      • endometrioid
        • unspecified site
          • male

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO039
Male reproductive system cancers - prostate
Default principal diagnosis: inpatient Yes · outpatient Yes

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary
Malig.
Secondary
Ca
in situ
BenignUncertainUnspec.
prostate (gland)C61C79.82D07.5D29.1D40.0D49.59

Patient EducationClinical

Prostate Cancer

Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen.

The full article covers:

  • What is prostate cancer?
  • What causes prostate cancer?
  • Who is more likely to develop prostate cancer?
  • What are the symptoms of prostate cancer?
  • What are prostate tests and how is prostate cancer diagnosed?
  • What are the treatments for prostate cancer?
  • Can prostate cancer be prevented?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C61 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
185 Malign neopl prostate
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C61Overview

Is C61 (Malignant neoplasm of prostate) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of prostate on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C61 group to?

When malignant neoplasm of prostate is the principal diagnosis on an inpatient stay, it groups to MS-DRG 715, 716, 722, 723, 724, with relative weights from 0.6117 to 2.2373 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of C61?

Under the General Equivalence Mappings, malignant neoplasm of prostate converts to ICD-9-CM 185 (malign neopl prostate). The mapping is a direct match.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.